Pharmaceutical Business review

Nventa presents additional positive data from Phase I neoplasia trial

HPV 16 E7-specific T-cell responses were elicited in all four subjects in the study’s third cohort following administration of 500mcg of HspE7 and 1,000mcg of Poly-ICLC, a potent toll-like receptor 3 (TLR-3) adjuvant. All T-cell responses represented significant changes from baseline, indicating that the responses were a direct result of treatment with HspE7.

Gregory McKee, president and CEO of Nventa, said: “We continue to be very encouraged with the immunological results from our Phase I HspE7 trial as they demonstrate that administration of HspE7 induces T-cell responses that we believe to be therapeutic. These positive immunological data, along with the safety data analyzed to date, provide a strong foundation for our Phase II trial expected to begin mid-2008.”